Adri Recio
University of Pennsylvania
11 Papers
111 Citations
Adri Recio is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Cancer & Mesothelioma. The author has an hindex of 9, co-authored 11 publications.
Chat about Author
Papers
Telomerase-Specific T-Cell Immunity in Breast Cancer: Effect of Vaccination on Tumor Immunosurveillance
Susan M. Domchek,Adri Recio,Rosemarie Mick,Carolyn E. Clark,Erica L. Carpenter,Kevin Fox,Angela DeMichele,Lynn M. Schuchter,Michael S. Leibowitz,Michael H. Wexler,Barbara A. Vance,Gregory L. Beatty,Elizabeth Veloso,Michael Feldman,Robert H. Vonderheide +14 more
TL;DR: It is suggested that hTERT-specific T cells could contribute to the immunosurveillance of breast cancer and suggest novel opportunities for both therapeutic and prophylactic vaccine strategies for cancer.
102
A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.
Daniel H. Sterman,Katherine L. Molnar-Kimber,Tara D. Iyengar,Michael Chang,Michael Lanuti,Kunjlata M. Amin,Brandon K Pierce,Eugene Kang,Joseph Treat,Adri Recio,Leslie A. Litzky,James M. Wilson,Larry R. Kaiser,Steven M. Albelda +13 more
TL;DR: The data suggest that systemic administration of steroids in the context of Ad-based gene delivery may limit acute clinical toxicity, but may not inhibit cellular and humoral responses to Ad vectors.
49
Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy
Avi I. Einzig,Lynn M. Schuchter,Adri Recio,Susan Coatsworth,Roberto Rodriquez,Peter H. Wiernik +5 more
TL;DR: Docetaxel has definite but low-level activity against malignant melanoma and should be considered in multidrug combination programs.
38
Interferon β adenoviral gene therapy in a patient with ovarian cancer
Daniel H. Sterman,Colin T. Gillespie,Richard G. Carroll,Christina M. Coughlin,Elaina M. Lord,Jing Sun,Andrew R. Haas,Adri Recio,Larry R. Kaiser,George Coukos,Carl H. June,Steven M. Albelda,Robert H. Vonderheide +12 more
TL;DR: A 47-year-old woman with a history of ovarian cancer and a 6-year disease-free remission presented with dyspnea and increased abdominal girth and was enrolled in a phase I clinical trial of adenoviral-mediated interferon β gene therapy.
27
Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC).
Andrew J. Rech,Rosemarie Mick,Adri Recio,AM DeMichele,Carol Kaplan Tweed,Kevin Fox,Susan M. Domchek,Robert H. Vonderheide +7 more
TL;DR: The FDA-approved anti-CD25 mab daclizumab was evaluated for its effect on Tregs in a phase I clinical study and the pneumococcal-conjugate vaccine (Prevnar), containing CRM-197 antigen to engage T cell help, was also administered.
8